Where to Buy Thymosin Alpha-1: 7 Purity & Identity Checks Before You Purchase

Thymosin Alpha-1 (TA1) is a 28-amino-acid immune-modulating peptide approved as a pharmaceutical drug in 35+ countries — making it one of the most clinically validated peptides available — but source quality matters more for TA1 than for shorter peptides because its longer sequence, required N-terminal acetylation, and injectable immune-modulating mechanism all create specific verification requirements that buyers must check before purchasing.

Originally isolated from thymus tissue by Dr. Allan Goldstein at George Washington University in 1972, TA1 modulates the immune system through T-cell maturation, dendritic cell activation, natural killer cell enhancement, and cytokine regulation. Its synthetic form — thymalfasin, marketed as Zadaxin — has been studied in meta-analyses for sepsis, randomized clinical trials for hepatitis B and C, and clinical investigations in cancer immunotherapy. As reviewed by King & Tuthill (2016), TA1 has been used clinically for immune modulation across dozens of countries for over two decades. For the complete mechanism and research overview, see the TA1 science deep-dive. For the broader immune and longevity peptide category, see the pillar page.

Source quality matters more for TA1 than for many other research peptides for 3 specific reasons: first, the 28-amino-acid sequence is longer than most commonly sourced peptides (BPC-157 is 15 amino acids, Ipamorelin is 5), making solid-phase peptide synthesis more complex and truncation or deletion errors more likely. Second, TA1's N-terminus is acetylated (Ac-Ser-...) — non-acetylated variants may have different biological activity and receptor binding. Third, as an injectable immune modulator, endotoxin contamination poses a specific risk: bacterial lipopolysaccharides could trigger inflammatory responses independent of the peptide's intended mechanism. Peptigrity maintains 24 independent lab tests for Thymosin Alpha-1 on the platform to help verify vendor quality claims.

7 Purity & Identity Checks for Thymosin Alpha-1

These 7 checks are specific to Thymosin Alpha-1 and account for its unique structural features — the 28-residue length, the N-terminal acetylation, and the ~3,108 Da molecular weight. Apply all 7 before purchasing from any vendor.

Check 1 — HPLC Purity (≥98%)

HPLC (High-Performance Liquid Chromatography) separates the target peptide from synthesis impurities and reports purity as a percentage of main peak area — and for Thymosin Alpha-1, demand ≥98% purity for research grade.

Lower purity is more concerning for TA1 than for shorter peptides because the most common impurities in 28-amino-acid synthesis are truncation products — peptide chains missing one or more amino acids from the sequence. These truncated fragments may retain partial bioactivity or interfere with the full-length peptide's mechanism. The HPLC chromatogram (the graphical readout showing the separation profile) must be included on the COA — a purity percentage without the chromatogram cannot be independently verified.

Check 2 — Mass Spectrometry Identity (~3,108 Da)

Mass spectrometry confirms the molecular identity of the peptide — the observed molecular weight must match the theoretical MW of Thymosin Alpha-1 at approximately 3,108.3 Da (±1 Da).

This is the check that catches wrong-compound substitution. A sample can be 99% pure by HPLC but still be the wrong peptide entirely — HPLC measures purity (how much of the sample is a single compound) while mass spectrometry measures identity (which compound it is). ESI-MS (Electrospray Ionization Mass Spectrometry) and MALDI-TOF are the standard methods. For TA1 specifically, verify that the observed MW accounts for the N-terminal acetyl group, which adds approximately 42 Da compared to the non-acetylated form.

Check 3 — N-Terminal Acetylation Verification

TA1's N-terminus is acetylated (Ac-Ser-Asp-Ala-Ala-Val...) — this is a critical structural feature that most buyers miss and most competitor buying guides do not mention.

Non-acetylated variants of TA1 have a different charge state at the N-terminus, which may affect receptor binding, biological activity, and peptide stability. The natural TA1 sequence includes the acetyl group, and published clinical research used the acetylated form (thymalfasin). If the product you receive is non-acetylated, it is structurally different from the compound studied in clinical trials.

How to verify: the mass spectrometry result should show a MW of ~3,108 Da (acetylated) rather than ~3,066 Da (non-acetylated — approximately 42 Da lower). Some COAs explicitly state "N-terminal acetylation confirmed" or list the sequence beginning with "Ac-Ser..." If neither the MW nor the COA text confirms acetylation, the modification status is unverified.

Check 4 — Amino Acid Sequence Confirmation (28 Residues)

The full Thymosin Alpha-1 sequence is Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN — 28 amino acids, with the N-terminal acetylation noted above.

At 28 residues, TA1 is significantly longer than many commonly sourced research peptides. Longer sequences have higher truncation and deletion error rates during solid-phase peptide synthesis (SPPS) — each coupling step has a yield below 100%, and errors compound over 28 cycles. Some vendors may sell truncated fragments or deletion sequences as "Thymosin Alpha-1" — these are cheaper to produce but are not the full-length, biologically characterized compound.

Mass spectrometry is the primary detection method: if the observed MW matches ~3,108 Da and the COA lists the complete 28-residue sequence, sequence integrity is highly likely. A MW that is lower by multiples of ~100–130 Da (the approximate weight of individual amino acids) suggests missing residues.

Check 5 — Batch-Specific COA

Every Certificate of Analysis must correspond to a specific synthesis batch — identified by a unique batch or lot number printed on both the COA and the product vial.

If the same COA appears across orders placed months apart, it is likely a generic document rather than a batch-specific test result. The testing date should be recent relative to the purchase date — a COA from 12+ months ago may not reflect the current product. For a full breakdown of documentation red flags, see the guide on COA red flags.

Check 6 — Endotoxin Testing

Endotoxins — lipopolysaccharides shed from gram-negative bacterial cell walls — are a specific concern for injectable immune-modulating peptides, and this check is more important for TA1 than for most other research peptides.

TA1 is designed to modulate the immune system. Endotoxin contamination in an immune-modulating injectable could trigger an inflammatory response entirely independent of the peptide's intended mechanism — producing fever, malaise, or systemic inflammation that may be mistakenly attributed to the peptide itself. Higher-quality vendors include endotoxin testing results on the COA, typically reporting levels below 0.25 EU/mg (Endotoxin Units per milligram). If a vendor does not test for endotoxins in an injectable immune peptide, that is a meaningful quality gap.

Check 7 — Independent Third-Party Testing

In-house testing by the vendor who also sells the product has an inherent conflict of interest — independent third-party testing from an accredited laboratory provides unbiased verification.

Peptigrity's lab test database includes 24 independent HPLC purity tests for Thymosin Alpha-1 across multiple vendors. Use these to cross-reference vendor purity claims against independently generated data. The shop reviews and trust scores provide an additional verification layer based on community experience and testing history. For the complete verification process, see how to verify peptide quality before you buy. For information on testing services, see the third-party testing labs directory.

Thymosin Alpha-1 vs Thymalin — Don't Confuse Them

Thymosin Alpha-1 and Thymalin are frequently confused but are completely different products — TA1 is a defined, single-sequence synthetic peptide with published clinical data, while Thymalin is a crude extract from bovine thymus glands containing a variable mixture of multiple thymic peptides.

A buyer searching for "thymosin alpha 1" who receives Thymalin has received a fundamentally different product. Thymalin's composition varies by batch because it is extracted from biological tissue rather than synthesized to a defined sequence. Standard peptide analytical methods (HPLC purity, mass spectrometry for a single MW) are less effective for verifying Thymalin quality because it is inherently a mixture — there is no single expected MW or purity percentage to match against.

The distinction matters: if a COA shows multiple peaks on the chromatogram without a dominant single peak at the expected TA1 MW, the product may be a thymic extract rather than pure synthetic Thymosin Alpha-1.

What Forms Is Thymosin Alpha-1 Available In?

Thymosin Alpha-1 is most commonly available as a lyophilized powder in 5 mg or 10 mg vials — the format used in the majority of published clinical research and the format that provides the highest quality verification confidence.

Lyophilized powder (vials): The standard research format. Requires reconstitution with bacteriostatic water before use. This is the most verifiable format — COA testing is performed on the powder, independent testing can be conducted on the same material, and storage conditions can be controlled precisely. Available in 5 mg and 10 mg sizes from most research peptide vendors.

Pre-mixed injectable pens: An emerging format that offers convenience (no reconstitution needed) but reduces dose flexibility and makes independent quality verification more difficult — you cannot send a pre-mixed pen to a testing lab as easily as a lyophilized vial.

Nasal spray: Some vendors offer TA1 nasal preparations, and there is notable search interest for this form (70 monthly searches for "thymosin alpha 1 nasal spray"). However, no published clinical trial has used intranasal Thymosin Alpha-1 — the majority of clinical research used subcutaneous injection. Bioavailability data for intranasal delivery of a 28-amino-acid peptide is limited. If pursuing nasal administration, verify that the formulation has independent testing confirming peptide identity and concentration in the solution.

Oral capsules: TA1 is a 28-amino-acid peptide that is expected to be degraded by gastrointestinal proteases before achieving meaningful systemic absorption. No published clinical trial has used oral TA1. Oral bioavailability for a peptide of this size and structure is expected to be very low.

What Does Thymosin Alpha-1 Cost?

Research-grade Thymosin Alpha-1 typically costs between $40–$90 per 5 mg vial and $60–$150 per 10 mg vial as of 2026, though pricing varies significantly by vendor — and the cheapest option with no quality verification is always more expensive than a verified source, because you may be paying for product that isn't what the label claims.

Research-grade TA1 from peptide vendors: pricing varies by purity level, vial size, and whether the vendor provides batch-specific COAs with full analytical data. Higher-priced vendors that include HPLC chromatograms, mass spectrometry results, endotoxin testing, and acetylation confirmation are providing measurable quality assurance — not just a vial of powder.

Compounded TA1 from licensed compounding pharmacies (prescription required): higher cost than research-grade, but manufactured under USP-compliant conditions with pharmaceutical-grade quality standards. This route requires a physician prescription and is subject to the regulatory status discussed below.

Zadaxin (pharmaceutical-grade thymalfasin): significantly more expensive than research-grade product, available in countries where it holds regulatory approval. The pharmaceutical version represents the highest manufacturing standard but is not available as a standalone prescription product in the United States.

Price should not be the primary selection criterion. Use Peptigrity's shop reviews and lab test data to compare quality verification data across vendors — then factor in pricing within the subset of vendors that pass the 7 checks above.

Regulatory Status — Is Thymosin Alpha-1 Legal to Buy?

Thymosin Alpha-1 is approved as a pharmaceutical drug (Zadaxin/thymalfasin) in 35+ countries but is not approved as a standalone prescription drug in the United States — though it is among the peptides expected to be reclassified from FDA Category 2 to Category 1 in 2026, which would restore access through licensed compounding pharmacies.

International: Zadaxin holds regulatory approval for immune modulation, hepatitis B/C treatment, and as a vaccine adjuvant across Latin America, Eastern Europe, the Middle East, and the Asia-Pacific region. In these jurisdictions, it is a prescription pharmaceutical with full regulatory oversight.

United States: TA1 was placed on the FDA's Category 2 restricted list in 2023, which restricted compounding pharmacies from preparing it. As of early 2026, approximately 14 of 19 Category 2 peptides — including TA1 — are expected to be reclassified to Category 1, which would allow compounding under physician prescription through 503A and 503B pharmacies. Research-grade TA1 is available under RUO (Research Use Only) designation for laboratory use. For the full regulatory breakdown, see the FDA regulatory timeline, the peptide legal status by country guide, and the compounding vs research peptide comparison.

Athletic competition: TA1 is on the WADA Prohibited List under peptide hormones and related substances. It is banned both in-competition and out-of-competition for athletes subject to anti-doping testing.

Red Flags When Buying Thymosin Alpha-1

The most common red flag specific to Thymosin Alpha-1 sourcing is a Certificate of Analysis that does not confirm N-terminal acetylation or shows a molecular weight that doesn't match the expected ~3,108 Da — both of which suggest the product may be a truncated fragment, a non-acetylated variant, or an entirely different peptide.

MW mismatch: A COA showing a mass spectrometry result significantly below ~3,108 Da (e.g., in the ~2,800–3,000 Da range) indicates a truncated sequence — missing amino acids from the full 28-residue chain. This is the most common synthesis error for longer peptides.

No acetylation confirmation: If the COA does not mention acetylation, does not show "Ac-" at the N-terminus in the sequence, and the MS result is ~42 Da below expected — the product is likely non-acetylated and structurally different from the clinically studied compound.

TA1/Thymalin conflation: A vendor listing "Thymosin Alpha-1" but describing a "thymus extract" or "thymic peptide blend" is selling Thymalin or a similar crude extract — not the defined synthetic peptide.

No endotoxin testing: For an injectable immune-modulating peptide, the absence of endotoxin testing represents a meaningful quality gap. Higher-quality vendors include this data.

Generic COA: A COA without a batch/lot number, without a chromatogram, without a testing date, or one that appears identical across multiple orders is likely a template document rather than a batch-specific test result.

Below-market pricing: TA1 priced dramatically below the $40–$90 range for 5 mg may indicate shorter sequences, lower purity, or bulk-imported product without independent verification.

Therapeutic claims: A vendor marketing RUO peptides with claims like "cures hepatitis," "treats cancer," or "boosts immunity" is making non-compliant medical claims. Research Use Only products cannot be legally marketed for therapeutic use. For more on identifying scam peptide shops, see the buyer protection guide. For the full purity standards framework, see the quality reference.

Frequently Asked Questions

Is thymosin alpha-1 the same as thymalfasin/Zadaxin?

Yes — thymalfasin is the International Nonproprietary Name (INN) for synthetic Thymosin Alpha-1, and Zadaxin is the brand name under which thymalfasin is marketed in 35+ countries. The amino acid sequence, molecular weight (~3,108 Da), and biological mechanism are identical. The difference is in manufacturing standards: Zadaxin is produced under pharmaceutical GMP conditions with full regulatory oversight, while research-grade TA1 is synthesized for laboratory use under varying quality standards. Both are the same 28-amino-acid acetylated peptide.

Should I buy 5 mg or 10 mg vials?

A 10 mg vial provides more product per reconstitution, reduces the number of vials needed for longer protocols, and often offers a lower per-milligram cost. A 5 mg vial is more appropriate for shorter protocols, for evaluating a new vendor's product quality before committing to larger purchases, or for applications where smaller quantities reduce waste from degradation before the vial is fully used. Both sizes should have individual, batch-specific COAs with all 7 checks described above.

How do I reconstitute thymosin alpha-1?

Add bacteriostatic water to the lyophilized vial — direct the water stream against the vial wall, not onto the powder. Gently swirl until dissolved; never shake. A common reconstitution ratio is 1–2 mL bacteriostatic water per 5 mg vial. TA1 powder is hygroscopic (absorbs moisture from the air), so work efficiently once the vial stopper is pierced and store reconstituted solution refrigerated at 2–8°C. Use within 3–4 weeks of reconstitution. For the full step-by-step process, see the reconstitution guide.

Is thymosin alpha-1 available as a nasal spray?

Some vendors offer TA1 nasal spray preparations, and there is meaningful search interest for this form. However, no published clinical trial has used intranasal Thymosin Alpha-1 — the majority of clinical research used subcutaneous injection. Bioavailability data for intranasal delivery of a 28-amino-acid peptide is limited, and absorption efficiency is uncertain. If pursuing nasal administration, verify that the formulation has independent testing confirming peptide identity, purity, and concentration in the solution — the same 7 checks apply to any TA1 product regardless of delivery format.

How does thymosin alpha-1 compare to thymosin beta-4 (TB-500)?

They are different peptides from the thymosin family with different mechanisms and different applications. Thymosin Alpha-1 (28 amino acids) modulates the immune system — T-cell maturation, dendritic cell activation, cytokine regulation, and NK cell enhancement. TB-500 (a synthetic fragment of Thymosin Beta-4, 43 amino acids) promotes tissue repair — cell migration, actin regulation, and angiogenesis. TA1 is used for immune support. TB-500 is used for healing and recovery. They are not interchangeable, but they can be used in separate protocols targeting different biological objectives. See the individual peptide guides for each compound's complete research profile.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.